Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Janus kinases in immune cell signaling.

Ghoreschi K, Laurence A, O'Shea JJ.

Immunol Rev. 2009 Mar;228(1):273-87. doi: 10.1111/j.1600-065X.2008.00754.x. Review.

2.

JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.

Vainchenker W, Dusa A, Constantinescu SN.

Semin Cell Dev Biol. 2008 Aug;19(4):385-93. doi: 10.1016/j.semcdb.2008.07.002. Epub 2008 Jul 17. Review.

PMID:
18682296
3.

Therapeutic targeting of Janus kinases.

Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ.

Immunol Rev. 2008 Jun;223:132-42. doi: 10.1111/j.1600-065X.2008.00644.x. Review.

4.

Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.

Constantinescu SN, Leroy E, Gryshkova V, Pecquet C, Dusa A.

Biochem Soc Trans. 2013 Aug;41(4):1048-54. doi: 10.1042/BST20130084. Review.

PMID:
23863177
5.

The use of structural biology in Janus kinase targeted drug discovery.

Alicea-Velázquez NL, Boggon TJ.

Curr Drug Targets. 2011 Apr;12(4):546-55. Review.

6.

Advances in the discovery of selective JAK inhibitors.

Menet CJ, Rompaey LV, Geney R.

Prog Med Chem. 2013;52:153-223. doi: 10.1016/B978-0-444-62652-3.00004-1. Review.

PMID:
23384668
7.

Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.

Dymock BW, See CS.

Expert Opin Ther Pat. 2013 Apr;23(4):449-501. doi: 10.1517/13543776.2013.765862. Epub 2013 Feb 1. Review.

PMID:
23367873
8.

The Janus kinases (Jaks).

Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ.

Genome Biol. 2004;5(12):253. Epub 2004 Nov 30. Review.

9.

JAK and MPL mutations in myeloid malignancies.

Tefferi A.

Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360. Review.

PMID:
18297515
10.

JAK2 the future: therapeutic strategies for JAK-dependent malignancies.

LaFave LM, Levine RL.

Trends Pharmacol Sci. 2012 Nov;33(11):574-82. doi: 10.1016/j.tips.2012.08.005. Epub 2012 Sep 17. Review.

PMID:
22995223
11.

Inborn errors of human JAKs and STATs.

Casanova JL, Holland SM, Notarangelo LD.

Immunity. 2012 Apr 20;36(4):515-28. doi: 10.1016/j.immuni.2012.03.016. Review.

12.

Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.

Kettle JG, Åstrand A, Catley M, Grimster NP, Nilsson M, Su Q, Woessner R.

Expert Opin Ther Pat. 2017 Feb;27(2):145-161. doi: 10.1080/13543776.2017.1252754. Epub 2016 Nov 4. Review.

PMID:
27774822
13.

Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.

Kettle JG, Åstrand A, Catley M, Grimster NP, Nilsson M, Su Q, Woessner R.

Expert Opin Ther Pat. 2017 Feb;27(2):127-143. doi: 10.1080/13543776.2017.1252753. Epub 2016 Nov 7. Review.

PMID:
27774824
14.

Mining for JAK-STAT mutations in cancer.

Constantinescu SN, Girardot M, Pecquet C.

Trends Biochem Sci. 2008 Mar;33(3):122-31. doi: 10.1016/j.tibs.2007.12.002. Review.

PMID:
18291658
15.

Lymphoid malignancies: Another face to the Janus kinases.

Scott LM.

Blood Rev. 2013 Mar;27(2):63-70. doi: 10.1016/j.blre.2012.12.004. Epub 2013 Jan 20. Review.

PMID:
23340138
16.

JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth.

Zouein FA, Duhé RJ, Booz GW.

Growth Factors. 2011 Dec;29(6):245-52. doi: 10.3109/08977194.2011.614949. Epub 2011 Sep 5. Review.

17.

Janus kinases and their role in growth and disease.

Aringer M, Cheng A, Nelson JW, Chen M, Sudarshan C, Zhou YJ, O'Shea JJ.

Life Sci. 1999;64(24):2173-86. Review.

PMID:
10374907
18.

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.

Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S.

Nat Rev Drug Discov. 2011 Feb;10(2):127-40. doi: 10.1038/nrd3264. Review. Erratum in: Nat Rev Drug Discov. 2011 Apr;10(4):318.

PMID:
21283107
19.

Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.

Levine RL, Wernig G.

Hematology Am Soc Hematol Educ Program. 2006:233-9, 510. Review.

PMID:
17124066
20.

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.

Rosenthal A, Mesa RA.

Expert Opin Pharmacother. 2014 Jun;15(9):1265-76. doi: 10.1517/14656566.2014.913024. Epub 2014 Apr 25. Review.

PMID:
24766055

Supplemental Content

Support Center